INSMED Inc 8-K Filing
Ticker: INSM · Form: 8-K · Filed: 2025-11-18T00:00:00.000Z
Sentiment: neutral
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-11-18 16:15:54
Key Financial Figures
- $0.01 — h registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select
Filing Documents
- ef20059077_8k.htm (8-K) — 30KB
- ef20059077_ex99-1.htm (EX-99.1) — 29KB
- image0.jpg (GRAPHIC) — 24KB
- 0001140361-25-042598.txt ( ) — 226KB
- insm-20251118.xsd (EX-101.SCH) — 4KB
- insm-20251118_lab.xml (EX-101.LAB) — 21KB
- insm-20251118_pre.xml (EX-101.PRE) — 16KB
- ef20059077_8k_htm.xml (XML) — 4KB
01 —
ITEM 7.01 — Regulation FD Disclosure. On November 18 , 2025, Insmed Incorporated (the "Company") issued a press release announcing that the European Commission (the "EC") has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis ("NCFB") in patients 12 years of age and older with two or more exacerbations in the prior 12 months. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 —
ITEM 8.01 — Other Events. On November 18 , 2025, the Company announced that the EC has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
01 —
ITEM 9.01 —
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on November 18, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2025 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary